Alkali burn versus suture-induced corneal neovascularization in C57BL/6 mice: An overview of two common animal models of corneal neovascularization

Experimental Eye Research

Volumn 121, Issue , 2014, Pages 1-4

  Giacomini, Chiara ^a   Ferrari, Giulio ^a   Bignami, Fabio ^a   Rama, Paolo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Alkali burn; Cornea; Lymphangiogenesis; Neovascularization; Suture

Indexed keywords

CD31 ANTIGEN; LYVE 1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANGIOGENESIS ASSAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL; CAUSTIC BURN; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA STROMA; ENDOTHELIAL PROGENITOR CELL; HEMANGIOGENESIS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LYMPH VESSEL; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; NYLON SUTURE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SLIT LAMP;

ALKALI BURN; CORNEA; LYMPHANGIOGENESIS; NEOVASCULARIZATION; SUTURE;

ANIMALS; ANTIGENS, CD31; BURNS, CHEMICAL; CORNEAL NEOVASCULARIZATION; CORNEAL STROMA; DISEASE MODELS, ANIMAL; EYE BURNS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLYCOPROTEINS; LYMPHANGIOGENESIS; MICE; MICE, INBRED C57BL; NYLONS; RETROSPECTIVE STUDIES; SODIUM HYDROXIDE; SUTURES; TIME FACTORS;

EID: 84895762943     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2014.02.005     Document Type: Article

References (15)

1. Bock F., Onderka J., et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest. Ophthalmol. Vis. Sci. 2007, 48(6):2545-2552.
2. Cheng S.F., Dastjerdi M.H., et al. Short-term topical bevacizumab in the treatment of stable corneal neovascularization. Am. J. Ophthalmol. 2012, 154(6):940-948. e941.
3. Cursiefen C., Maruyama K., et al. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J.Exp. Med. 2011, 208(5):1083-1092.
4. Dietrich T., Bock F., et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J.Immunol. 2010, 184(2):535-539.
5. Ferrari G., Bignami F., et al. Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring. Invest. Ophthalmol. Vis. Sci. 2013, 54(3):1680-1688.
6. Fournier G.A., Lutty G.A., et al. Acorneal micropocket assay for angiogenesis in the rat eye. Invest. Ophthalmol. Vis. Sci. 1981, 21(2):351-354.
7. Gimbrone M.A., Cotran R.S., et al. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J.Natl. Cancer Inst. 1974, 52(2):413-427.
8. Kenyon B.M., Voest E.E., et al. Amodel of angiogenesis in the mouse cornea. Invest. Ophthalmol. Vis. Sci. 1996, 37(8):1625-1632.
9. Liu F., Smith J., et al. Genetic heterogeneity of skin microvasculature. Dev. Biol. 2010, 340(2):480-489.
10. Muthukkaruppan V., Auerbach R. Angiogenesis in the mouse cornea. Science 1979, 205(4413):1416-1418.
11. Regenfuss B., Onderka J., et al. Genetic heterogeneity of lymphangiogenesis in different mouse strains. Am. J. Pathol. 2010, 177(1):501-510.
12. Rohan R.M., Fernandez A., et al. Genetic heterogeneity of angiogenesis in mice. FASEB J. 2000, 14(7):871-876.
13. Shaked Y., Bertolini F., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell. 2005, 7(1):101-111.
14. Shi W., Ming C., et al. Features of corneal neovascularization and lymphangiogenesis induced by different etiological factors in mice. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249(1):55-67.
15. Steven P., Bock F., et al. Intravital two-photon microscopy of immune cell dynamics in corneal lymphatic vessels. PLoS One 2011, 6(10):e26253.